[Protective effect of aminophylline on cerebral injury during cardiopulmonary bypass in infants].
OBJECTIVE
To investigate the protective effect of aminophylline on cerebral injury induced by cardiopulmonary bypass (CPB) in infants.


METHODS
Forty patients who underwent ventricular septal defect within 3 years old were randomly divided into 2 groups(20 cases in each group).Aminophylline group:aminophylline (5 mg/kg) was injected slowly via the vein after anesthesia and maintained at a dose of 0.5 mg/(kg.h) until the end of CPB.


METHODS
aminophylline was replaced by Ringer's lactated solution. Samples were obtained at the beginning of CPB (T(1)),the end of CPB (T(2)),6 h (T(3)) and 24 h (T(4)) after the operation to measure S-100 beta protein, NSE, tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), and interleukin-10 (IL-10) concentration by ELISA in the 2 groups.


RESULTS
Compared with the time point immediately before CPB, the S-100beta protein,NSE, TNF-alpha, and IL-8 concentration in the 2 groups began to increase with the start of CPB, reached a climax at the end of CPB (T(2)),decreased gradually 6 h after the termination of CPB(T(3)) and could not restore to the level before CPB at T(4)(24 h after the termination of CPB).IL-10 in the 2 groups both increased after the CPB. At T(2) and T(3), S-100beta protein,NSE, TNF-alpha, and IL-8 concentrations were significantly lower than those in the aminophylline group (P<0.05 or P<0.01), while IL-10 was just the opposite.


CONCLUSIONS
There is cerebral damage induced by CPB. Aminophylline may play a protective role in cerebral injury by modulating the balance between the pro-inflammatory factor and anti-inflammatory factor to reduce the level of S-100beta protein and NSE during CPB and open cardiac surgeries.
Pan
Shan
S
Department of Thoracic Surgery, Fuzhou Pulmonary Hospital, Fuzhou Fujian 350000,China.
Lin
Guoqiang
G
Jiang
Haihe
H
Huang
Rimao
R
D000628:Aminophylline / Q000008:administration & dosage / Q000627:therapeutic use*; D001927:Brain Diseases / Q000209:etiology / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D013504:Cardiovascular Surgical Procedures; D002675:Child, Preschool; D005260:Female; D006343:Heart Septal Defects / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D009414:Nerve Growth Factors / Q000097:blood; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood
D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D000628:Aminophylline